Literature DB >> 10199779

Characterization of human iodothyronine sulfotransferases.

M H Kester1, E Kaptein, T J Roest, C H van Dijk, D Tibboel, W Meinl, H Glatt, M W Coughtrie, T J Visser.   

Abstract

Sulfation is an important pathway of thyroid hormone metabolism that facilitates the degradation of the hormone by the type I iodothyronine deiodinase, but little is known about which human sulfotransferase isoenzymes are involved. We have investigated the sulfation of the prohormone T4, the active hormone T3, and the metabolites rT3 and 3,3'-diiodothyronine (3,3'-T2) by human liver and kidney cytosol as well as by recombinant human SULT1A1 and SULT1A3, previously known as phenol-preferring and monoamine-preferring phenol sulfotransferase, respectively. In all cases, the substrate preference was 3,3'-T2 >> rT3 > T3 > T4. The apparent Km values of 3,3'-T2 and T3 [at 50 micromol/L 3'-phosphoadenosine-5'-phosphosulfate (PAPS)] were 1.02 and 54.9 micromol/L for liver cytosol, 0.64 and 27.8 micromol/L for kidney cytosol, 0.14 and 29.1 micromol/L for SULT1A1, and 33 and 112 micromol/L for SULT1A3, respectively. The apparent Km of PAPS (at 0.1 micromol/L 3,3'-T2) was 6.0 micromol/L for liver cytosol, 9.0 micromol/L for kidney cytosol, 0.65 micromol/L for SULT1A1, and 2.7 micromol/L for SULT1A3. The sulfation of 3,3'-T2 was inhibited by the other iodothyronines in a concentration-dependent manner. The inhibition profiles of the 3,3'-T2 sulfotransferase activities of liver and kidney cytosol obtained by addition of 10 micromol/L of the various analogs were better correlated with the inhibition profile of SULT1A1 than with that of SULT1A3. These results indicate similar substrate specificities for iodothyronine sulfation by native human liver and kidney sulfotransferases and recombinant SULT1A1 and SULT1A3. Of the latter, SULT1A1 clearly shows the highest affinity for both iodothyronines and PAPS, but it remains to be established whether it is the prominent isoenzyme for sulfation of thyroid hormone in human liver and kidney.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199779     DOI: 10.1210/jcem.84.4.5590

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

Review 2.  Sulfotransferase genetic variation: from cancer risk to treatment response.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Drug Metab Rev       Date:  2013-09-06       Impact factor: 4.518

3.  NPY and MC4R signaling regulate thyroid hormone levels during fasting through both central and peripheral pathways.

Authors:  Kristen R Vella; Preeti Ramadoss; Francis S Lam; Jamie C Harris; Felix D Ye; Paul D Same; Nicholas F O'Neill; Eleftheria Maratos-Flier; Anthony N Hollenberg
Journal:  Cell Metab       Date:  2011-11-17       Impact factor: 27.287

4.  Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie".

Authors:  Zoe Riches; Emma L Stanley; Jackie C Bloomer; Michael W H Coughtrie
Journal:  Drug Metab Dispos       Date:  2009-08-13       Impact factor: 3.922

5.  Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics.

Authors:  Craig M Butt; Heather M Stapleton
Journal:  Chem Res Toxicol       Date:  2013-10-21       Impact factor: 3.739

6.  American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models.

Authors:  Antonio C Bianco; Grant Anderson; Douglas Forrest; Valerie Anne Galton; Balázs Gereben; Brian W Kim; Peter A Kopp; Xiao Hui Liao; Maria Jesus Obregon; Robin P Peeters; Samuel Refetoff; David S Sharlin; Warner S Simonides; Roy E Weiss; Graham R Williams
Journal:  Thyroid       Date:  2013-12-12       Impact factor: 6.568

7.  Brominated flame retardants in placental tissues: associations with infant sex and thyroid hormone endpoints.

Authors:  Christopher Leonetti; Craig M Butt; Kate Hoffman; Stephanie C Hammel; Marie Lynn Miranda; Heather M Stapleton
Journal:  Environ Health       Date:  2016-11-25       Impact factor: 5.984

8.  Treatment of Hypothyroid Patients With L-Thyroxine (L-T4) Plus Triiodothyronine Sulfate (T3S). A Phase II, Open-Label, Single Center, Parallel Groups Study on Therapeutic Efficacy and Tolerability.

Authors:  Ferruccio Santini; Giovanni Ceccarini; Caterina Pelosini; Monica Giannetti; Ilaria Ricco; Giorgia Querci; Enzo Grossi; Giorgio Saponati; Paolo Vitti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-29       Impact factor: 5.555

Review 9.  Estrogen Sulfotransferase (SULT1E1): Its Molecular Regulation, Polymorphisms, and Clinical Perspectives.

Authors:  MyeongJin Yi; Masahiko Negishi; Su-Jun Lee
Journal:  J Pers Med       Date:  2021-03-11

10.  Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.

Authors:  Melissa Runge-Morris; Thomas A Kocarek
Journal:  PPAR Res       Date:  2009-08-10       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.